General Information of Drug (ID: DM548TK)

Drug Name
Belumosudil Drug Info
Synonyms KD025
Indication
Disease Entry ICD 11 Status REF
Graft-versus-host disease 4B24 Approved [1]
Psoriasis vulgaris EA90 Phase 2 [2]
Rheumatoid arthritis FA20 Phase 2 [3]
Psoriatic arthritis FA21 Phase 1 [4]
Scleroderma 4A42 Phase 1 [4]
Systemic lupus erythematosus 4A40.0 Phase 1 [4]
Cross-matching ID
PubChem CID
11950170
CAS Number
CAS 911417-87-3
TTD Drug ID
DM548TK

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
INS-117548 DMA46DO Glaucoma/ocular hypertension 9C61 Phase 1 [6]
GSK269962A DM5I2HL Inflammation 1A00-CA43.1 Clinical trial [7]
PMID28048944-Compound-19 DMPT3V9 N. A. N. A. Patented [8]
PMID28048944-Compound-3 DM1BN74 N. A. N. A. Patented [8]
PMID28048944-Compound-7 DMXZ368 N. A. N. A. Patented [8]
PMID28048944-Compound-4 DMJAUWG N. A. N. A. Patented [8]
PMID28048944-Compound-5 DMAB987 N. A. N. A. Patented [8]
PMID28048944-Compound-6 DM5RCBV N. A. N. A. Patented [8]
PMID28048944-Compound-2 DM9ZXOP N. A. N. A. Patented [8]
Tricyclic compound 7 DME84S5 N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Rho-associated protein kinase 2 (ROCK2) TTGWKQJ ROCK2_HUMAN Inhibitor [5]

References

1 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 214783.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02317627) Study of of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
8 Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.